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Abstract Although mitral regurgitation (MR) is the
most common valvular heart disease, it should be
regarded as a complex multifactorial disease that
involves multiple entities. Optimal medical ther-
apy alone does not hinder the progression of the
disease, and in the 1980s it was already recognised
that corrective surgery is indicated if MR is severe
and patients are symptomatic (except for those with
the most severe left ventricle dysfunction). Later
on, asymptomatic patients with deterioration of the
left ventricular ejection fraction were also operated
on to avoid irreversible left ventricular dysfunction,
heart failure and eventually death. However, a major
drawback remains the fact that a significant group of
patients is considered to have a high perioperative
risk due to their advanced age or severe comorbidi-
ties. Since less invasive, percutaneous interventions
have been developed and recently thoroughly inves-
tigated in the MITRA-FR and the COAPT studies, the
type of intervention and also the timing have become
more crucial. In this critical review of the literature,
we describe what we should have learned from the
past and which (haemodynamic) parameters can best
predict the outcome in patients with MR.
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Introduction
Until the 1980s, mitral regurgitation (MR) was mainly
diagnosed by right heart catheterisation in combina-
tion with left ventricular cine-angiography. Increased
right-sided pressures, such as pulmonary artery and
pulmonary wedge pressure, and in particular the pres-
ence of an early and/or high V wave, suggested the
presence of MR. Moreover, an enlarged left ventricle
as well as left atrium could be seen during left ventric-
ular (LV) angiography. The grade of MR was mainly
estimated from the shape and volume of contrast fluid
in the left atrium. All of these values were used as
criteria for surgery. The advancement of echocardio-
graphic techniques, such as Doppler measurements,
offered additional diagnostic possibilities and eventu-
ally largely replaced invasive and angiographic meth-
ods in daily clinical practice.
Although considerations were made carefully with
the aforementioned entities in the past, the post-
operative results were sometimes disappointing. In
order to search for criteria that could predict surgi-
cal success, several studies on the haemodynamics
of MR have been published [1–3]. Current guidelines
state that surgical intervention should be based on the
severity of MR, patient symptoms, LV systolic function
≤60% or LV end-systolic diameter (LVESD) ≥45mm,
presence of atrial fibrillation and systolic pulmonary
artery pressure of more than 50mmHg [4]. However,
at the same time, patients referred to undergo surgery
earlier in the natural process of the disease have been
shown to have a better outcome in terms of survival
compared to patients that were treated according to
the criteria in these guidelines [5]. Nowadays, a trend
is observed to advise patients to undergo surgery
when there is a high likelihood of successful mitral
valve (MV) repair (if LVESD ≥40mm and flail leaflet
and/or left atrial (LA) volume ≥60ml/m2).
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Not only are the criteria for MV surgery chang-
ing continuously, but the introduction of novel percu-
taneous edge-to-edge transcatheter MV repair tech-
niques (MitraClip, Abbott Vascular, Menlo Park, CA,
USA) also warrants comprehensive knowledge on the
part of the treating physicians. Lessons learned from
the past in haemodynamics and MV surgery could be
essential for further improvements in patient selection
and timing of the procedure.
Haemodynamics in MR
The Frank-Starling curve shows the relation between
LV stroke volume (LVSV) and LV end-diastolic volume
(LVEDV) (Fig. 1). The essence of this curve is the
fact that the LVSV increases as a response to an in-
creased LVEDV, which is caused by stretching the my-
ocardium and improving contractility. However, when
improved contractility as a compensation mechanism
comes to an end, the left ventricle gradually dilates
(remodelling) and its compliance increases (Fig. 1).
Subsequently LV eccentric hypertrophy develops and
causes diastolic as well as systolic LV dysfunction [1,
6]. In addition, according to the LaPlace law, wall
stress is proportional to pressure and chamber size
and inversely proportional to wall thickness.
LV wall stress= LV pressure×LV radius
2×LV wall thickness
Thus, increased LVEDV and LV end-diastolic pres-
sure (LVEDP) will result in an increased LV end-di-
astolic wall stress [1]. Also an increase in LV holosys-
tolic wall stress (LVHSWS), representing afterload dur-
ing the whole systole, is observed due to increased LV
end-systolic volume (LVESV) (Fig. 2). Since myocar-
dial blood perfusion depends on wall stress, increased
LV wall stress may cause subendocardial ischaemia
and subsequently myocardial fibrosis [1, 6–9].
Fig. 1 The Frank-Starling relationship is the observation that
ventricular output increases as preload (end-diastolic volume)
increases. LV left ventricular
Fig. 2 Left ventricular (LV) wall stress-volume loops in the
three stages of chronic mitral regurgitation (MR). As the ven-
tricle adapts to the chronic haemodynamic burden, a pro-
gressive increase in LV holosystolic as well as end-diastolic
wall stress occurs. LV ejection fraction progressively declines
from 65% in compensated MR, to 55% during the transitional
stage, and finally to 45% (or lower) in decompensated MR.
(Adapted from Gaasch and Meyer [1])
Not only the left ventricle, but also the left atrium
shows enlargement due to volume overload, which
reflects the severity and duration of the MR. There is
a close relationship between LA diameter and mor-
tality, with a more than 3-fold increase in mortality
when the LA diameter ≥55mm [10]. In contrast to
the LV dimensions, the LA dimension is affected to
a lesser degree by acute loading changes and there-
fore is a good marker for the average LA pressure for
a longer time period.
Lessons from MV surgery
In 1984, Zile et al. investigated the effect of several
preoperative LV echocardiographic parameters on
clinical symptoms after MV replacement in 20 pa-
tients with chronic MR [3]. They concluded that
patients with preoperative LV end-diastolic dimen-
sion of more than 4.0cm/m2, LVESD of more than
2.6cm/m2 and LV end-systolic wall stress of more
than 195mmHg (260 kdyn/cm2) remained symp-
tomatic postoperatively, despite continued medical
therapy. These observations led to the understanding
that earlier intervention could lead to better outcome
in these patients. More than 20 years later, Gaasch and
Meyer proposed the use of three stages of chronic MR.
Stage 1 consisted of a chronic compensated state with
LV enlargement, eccentric hypertrophy and normal
systolic function. Subsequently, there was a transi-
tional phase (stage 2) with mild LV dysfunction that is
reversible after surgical correction of the regurgitant
lesion. Finally, stage 3 was a decompensated MR
with progressive and irreversible structural and func-
tional changes in the ventricle [1]. When analysing
the LV wall stress-volume loops of these three stages,
it is apparent that the LVEDV, LVESV and LVHSWS
increase with every stage (Fig. 2). Moreover, the LV
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ejection fraction (LVEF) declines from 65% to 45% or
less. The authors concluded with three recommenda-
tions. First, corrective surgery is indicated if the MR
is severe. Second, the symptoms should be assessed
and evaluated. In the absence of cardiac symptoms,
many physicians hesitate to recommend surgery, un-
less clear and reliable LV dysfunction exists, or some
other factor (e.g. the development of atrial fibrillation)
must be considered. In contrast, surgery is indicated
in symptomatic patients regardless of whether LV
function is normal or abnormal (except for those with
the most severe LV dysfunction). Third, the func-
tional state of the left ventricle must be evaluated.
Corrective surgery should be considered in an asymp-
tomatic patient when the LVEF enters the transitional
stage (LVEF 50–60%) and is strongly recommended
before the LVEF is less than 50%. It should be noted
that these recommendations are based on data from
studies performed in the 1980s.
Transcatheter treatment of MR
In 1998, Maisano et al. published an operative tech-
nique by means of which they approximated the mi-
tral leaflets, creating a double-orifice MV, in order to
diminish MR [11]. The technique was simple, eas-
ily reproducible and effective. Based on this edge-to-
edge surgical technique, the MitraClip was developed
and introduced in 2014. This percutaneous device can
clip the edges of theMV leaflets in the samemanner as
the surgical technique proposed earlier. This method
offered new opportunities for high-risk patients.
A decade ago, Siegel et al. studied the acute
haemodynamic effects of MitraClip implantation by
right heart catheterisation and echocardiography un-
der general anaesthesia [12]. Significant improve-
ments were found in cardiac output (5.0 l/min± 2.0
to 5.7 l/min± 1.9; p= 0.003), and better LV unloading
manifested by a decrease in LVEDP (11.4mmHg± 9.0
to 8.8mmHg± 5.8; p=0.016) and subsequently signif-
icantly lower systemic vascular resistance (1226dyn·
s/cm–5± 481 to 1004dyn·s/cm–5± 442; p<0.001). More-
over, none of the patients had developed an acute
postprocedural low cardiac output state, which oc-
curred occasionally after surgical MV repair.
More recently, two important studies (MITRA-FR
and COAPT studies) investigating transcatheter MV
repair found conflicting results [13, 14]. The MITRA-
FR study showed no difference between the interven-
tion and the control group for the primary composite
endpoint (mortality or heart failure hospitalisation),
while the authors reporting on the COAPT trial con-
cluded that the MitraClip procedure reduces the rates
of hospitalisation for heart failure and all-cause mor-
tality within 2 years of follow-up compared to medical
therapy alone. The number needed to treat to prevent
one hospitalisation for heart failure within 24 months
was 3.1 patients. Apart from the number of patients
in the two trials (304 vs 614), the baseline echocar-
diographic characteristics were also different. COAPT
enrolled a subset of patients who had more severe MR
and less advanced LV disease compared to MITRA-FR
patients.
Furthermore, a more aggressive strategy for correc-
tion of MR was applied in COAPT, as suggested by
the larger number of clips implanted per patient in
COAPT than in MITRA-FR. Moreover, the rate of sus-
tained reduction of MR was higher in COAPT than in
MITRA-FR. The lower sustained efficacy of the Mitra-
Clip procedure may also have contributed to the lack
of benefit of the intervention in MITRA-FR. Both trials
required that patients remained symptomatic (New
York Heart Association (NYHA) class≥ II) despite the
use of guideline-directed medical therapy (GDMT) for
chronic systolic heart failure. However, COAPT im-
posed more demanding criteria for the inclusion of
patients, namely the use of maximal tolerated doses of
GDMT, and treatment with cardiac resynchronisation
therapy, defibrillators and revascularisation, if appro-
priate. Hence, in COAPT, medical treatment was op-
timised prior to randomisation and only a few major
adjustments in treatment occurred during follow-up.
On the other hand, in MITRA-FR medical therapy was
not optimised in all patients at baseline and multi-
ple adjustments in medical treatment were allowed in
each arm during follow-up. This issue may also have
decreased the ability to reveal a beneficial effect of the
intervention in MITRA-FR.
In view of these findings, Pibarot et al. concluded
that, to achieve a reduction in heart failure hospitali-
sation and mortality by the MitraClip procedure, pa-
tients had to meet the following three criteria [15]:
1. ≥moderate-to-severe (grade 3+) secondary MR de-
fined as effective regurgitant orifice area ≥30mm2
and/or regurgitant volume >45ml.
2. LVEF between 20% and 50% and LVESD <70mm.
3. Persistent heart failure symptoms (NYHA≥ II) de-
spite optimal (maximally) tolerated GDMT with
cardiac resynchronisation and coronary revascular-
isation if appropriate.
Conclusion
Based on all these historical data, it can be expected
that the benefit of treatment depends on the degree
of MV disease. It is hypothesised that selection of pa-
tients, based on the criteria above, could be further
improved by also measuring haemodynamic parame-
ters as performed in the past [12, 16]. From this point
of view, the LaPlace formula is important in under-
standing the various states of MR that can alter oxygen
demand, resulting in subendocardial ischaemia and,
subsequently, dyspnoea. Further insight will come
from future studies.
Conflict of interest A. Bergstra, C. Simsek and A.F.M. van den
Heuvel declare that they have no competing interests.






Open Access This article is licensed under a Creative Com-
mons Attribution 4.0 International License, which permits
use, sharing, adaptation, distribution and reproduction in
anymedium or format, as long as you give appropriate credit
to the original author(s) and the source, provide a link to
the Creative Commons licence, and indicate if changes were
made. The images or other third party material in this article
are included in the article’sCreativeCommons licence, unless
indicated otherwise in a credit line to thematerial. If material
is not included in the article’s Creative Commons licence and
your intended use is not permitted by statutory regulation or
exceeds the permitted use, you will need to obtain permis-
sion directly from the copyright holder. To view a copy of this
licence, visit http://creativecommons.org/licenses/by/4.0/.
References
1. Gaasch WH, Meyer TE. Left ventricular response to mitral
regurgitation. Circulation. 2008;118:2298–303.
2. Wisenbauch T, Spann JF, Carabello BA. Differences in my-
ocardial performance and load between patients with
similar amounts of chronic aortic versus chronic mitral
regurgitation. JAmCollCardiol. 1984;3:916–23.
3. Zile MR, Gaasch WH, Carroll JD, et al. Chronic mitral
regurgitation: predictivevalueofpreoperativeechocardio-
graphic indexes of left ventricular function andwall stress.
JAmCollCardiol. 1984;3:235–42.
4. Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS
Guidelines for the management of valvular heart disease.
EurHeartJ.2017;38(36):2739–91.
5. Tribouilloy C, Grigioni F, Avierinos JF, et al. Survival im-
plication of left ventricular end-systolic diameter inmitral
regurgitation due to flail leaflets: a long-term follow-up
multicenterstudy. JAmCollCardiol. 2009;54(21):1961–8.
6. Achmed MI, Gladden JD, Litovsky SH, et al. Increased ox-
idativestressandcardiomyocytemyofibrillardegeneration
in patients with chronic isolated mitral regurgitation and
ejectionfraction>60%. JAmCollCardiol. 2010;55:671–9.
7. ShudoY,TaniguchiK,TakedaK,etal. Assessmentofregional
myocardial wall stress before and after surgical correction
of functional ischaemicmitral regurgitationusingmultide-
tector computed tomography and novel software system.
EurJCardiothoracSurg. 2010;38:163–70.
8. van den Heuvel AFM, van Veldhuisen DJ, van der Wall EE,
et al. Regional myocardial blood flow reserve impairment
andmetabolic changes suggestingmyocardial ischemia in
patientswith idiopathicdilatedcardiomyopathy. J AmColl
Cardiol. 2000;35:19–28.
9. vandenHeuvelAFM,Bax JJ,BlanksmaPK,etal. Abnormal-
ities inmyocardial contractility,metabolismandperfusion
reserve in non-stenotic coronary segments in heart failure
patients. CardiovascRes. 2002;55:97–103.
10. RusinaruD, TribouilloyC, GrigioniF, et al. Left atrial size is
apotentpredictorofmortality inmitral regurgitationdueto
flail leaflets: results from a large international multicenter
study. CircCardiovascImaging. 2011;4(5):473–81.
11. Maisano F, Torracca L, Oppizzi M, et al. The edge-to-
edge technique: a simplified method to correct mitral
insufficiency. EurJCardiothoracSurg. 1998;13(3):240–5.
12. Siegel RJ, Biner S, Rafique AM, et al. The acute hemo-
dynamic effects of MitraClip therapy. J Am Coll Cardiol.
2011;57:1658–65.
13. Obadia JF, Messika-Zeitoun D, Leurent G, et al. Percu-
taneous repair or medical treatment for secondary mitral
regurgitation.NEngl JMed. 2018;379:2297–306.
14. Stone GW, Lindenfeld J, AbrahamWT, et al. Transcatheter
mitral-valve repair in patients with heart failure. N Engl J
Med. 2018;379:2307–18.
15. Pibarot P, Delgado V, Bax JJ. Mitra-FR vs. COAPT: lessons
from two trials with diametrically opposed results. Eur
HeartJCardiovascImaging. 2019;20:620–4.
16. Gaemperli O, Biaggi P, Gugelmann R, et al. Real-time left
ventricular pressure-volume loops during percutaneous
mitral valve repairwith theMitralClip system. Circulation.
2013;127:1018–27.
Mitral regurgitation: when to intervene? 271
